Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
2
×
clinical trials
life sciences
national blog main
national top stories
new york blog main
san diego blog main
san francisco blog main
vertex pharmaceuticals
american society of clinical oncology (asco)
anti-inflammatory drugs
arcturus therapeutics
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
avrobio
bluebird bio
boston
boulder/denver blog main
boulder/denver top stories
brexanolone
camp4 therapeutics
cancer
cancer immunotherapy
crispr therapeutics
crispr-cas9
deals
denali therapeutics
detroit blog main
detroit top stories
duchenne muscular dystrophy
dyne therapeutics
eidos therapeutics
estradiol
f-star gamma
facioscapulohumeral muscular dystrophy
fda
What
drug
2
×
reach
2
×
ago
ahead
ambien
american
annual
asco
attendees
attention
biotech
biotechs
camp’s
cancer
cash
chicago
city
clinical
combinations
community’s
considering
data
days
diseases
dyne
early
expanding
expected
experimental
eyes
focus
genetic
having
home
humans
ipo
ipos
key
kicks
long
Language
unset
Current search:
reach
×
drug
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
